Home

Christoph H Westphal

CIK 1291961 · President and CEO · last filed 2021-07-22

Christoph H Westphal is a President and CEO who has filed 106 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for TCRX, was dated Jul 22, 2021. Across all open-market trades the lifetime net is +$13.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.20M

Companies

5

Total Filings

106

Lifetime Open-Market Net

$13.59M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TCRX 10%+ Owner 1,036,585 $0.77 $796.4K $2.00M 1 2021-07-22
Salarius Pharmaceuticals, Inc. (FLKS) Delisted President and CEO 157,645 — — $3.19M 65 2018-10-18
VSTM Executive Chairman 65,911 $6.08 $400.7K $8.08M 28 2015-07-01
Tempest Therapeutics, Inc. (OVAS) Delisted Director 47,118 — — $1.05M 3 2014-03-11
Sirtris Pharmaceuticals, Inc. (SIRT) Delisted President and CEO 744,053 — — -$733.3K 8 2008-05-30

Recent Filings

106 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-07-22 TCRX Mixed +1,278,838 $2.00M EDGAR
2018-10-18 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Sell (S) −3,212,861 -$2.94M EDGAR
2017-07-27 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Grant (A) — $0 EDGAR
2016-11-08 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Buy (P) +7,000 $51.2K EDGAR
2016-11-07 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Buy (P) +8,870 $50.6K EDGAR
2016-06-24 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Buy (P) +2,700 $30.5K EDGAR
2016-06-22 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Buy (P) +5,700 $63.0K EDGAR
2016-06-21 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Buy (P) +6,000 $67.0K EDGAR
2016-06-17 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Buy (P) +5,800 $64.8K EDGAR
2016-06-15 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Buy (P) +5,900 $68.1K EDGAR
Showing 1–10 of 106
Page 1 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.